Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 12 de 12
1.
Article En | MEDLINE | ID: mdl-28826637

Few studies have addressed the effects of caffeine in the puberty and/or adolescence in a sex dependent manner. Considering that caffeine intake has increased in this population, we investigated the behavioral and synaptic proteins changes in pubescent male and female rats after maternal consumption of caffeine. Adult female Wistar rats started to receive water or caffeine (0.1 and 0.3g/L in drinking water; low and moderate dose, respectively) during the active cycle at weekdays, two weeks before mating. The treatment lasted up to weaning and the offspring received caffeine until the onset of puberty (30-34days old). Behavioral tasks were performed to evaluate locomotor activity (open field task), anxious-like behavior (elevated plus maze task) and recognition memory (object recognition task) and synaptic proteins levels (proBDNF, BDNF, GFAP and SNAP-25) were verified in the hippocampus and cerebral cortex. While hyperlocomotion was observed in both sexes after caffeine treatment, anxiety-related behavior was attenuated by caffeine (0.3g/L) only in females. While moderate caffeine worsened recognition memory in females, an improvement in the long-term memory was observed in male rats for both doses. Coincident with memory improvement in males, caffeine increased pro- and BDNF in the hippocampus and cortex. Females presented increased proBDNF levels in both brain regions, with no effects of caffeine. While GFAP was not altered, moderate caffeine intake increased SNAP-25 in the cortex of female rats. Our findings revealed that caffeine promoted cognitive benefits in males associated with increased BDNF levels, while females showed less anxiety. Our findings revealed that caffeine promotes distinct behavioral outcomes and alterations in synaptic proteins during brain development in a sex dependent manner.


Anxiety , Brain/growth & development , Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Memory/drug effects , Motor Activity/drug effects , Animals , Anxiety/etiology , Anxiety/metabolism , Anxiety/pathology , Brain/cytology , Brain/drug effects , Brain/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Dose-Response Relationship, Drug , Drinking Water , Female , Glial Fibrillary Acidic Protein/metabolism , Male , Memory/physiology , Motor Activity/physiology , Rats, Wistar , Sex Characteristics , Sexual Maturation , Synaptosomal-Associated Protein 25/metabolism
2.
Physiol Behav ; 170: 47-53, 2017 03 01.
Article En | MEDLINE | ID: mdl-27890589

Caffeine is the psychostimulant most consumed worldwide. Anxiogenic effects of caffeine have been described in adult animals with controversial findings about its anxiogenic potential. Besides, the effects of caffeine on anxiety with aging are still poorly known. In this study, adult mice (6months old) started to receive caffeine (0.3 and 1.0mg/mL, drinking water) during 12-14months only in the light cycle and at weekdays. The open field (OF) and elevated plus maze (EPM) testing were used to determine the effects of caffeine on anxiety-related behavior in adult and aged mice (18-20months old). Because aging alters synaptic proteins, we also evaluated SNAP-25 (as a nerve terminals marker), GFAP (as an astrocyte marker) and adenosine A1 and A2A receptors levels in the cortex. According to the OF analysis, caffeine did not change both hypolocomotion and anxiety with aging. However, aged mice showed less anxiety behavior in the EPM, but after receiving caffeine (0.3mg/mL) during adulthood they were anxious as adult mice. While SNAP-25 and adenosine A2A receptors increased with aging, both GFAP and adenosine A1 receptors were not affected. Caffeine at moderate dose prevented the age-related increase of the SNAP-25, with no effect on adenosine A2A receptors. The absence of effect for the highest dose suggests that tolerance to caffeine may have developed over time. Aged mice showed high responsiveness to the OF, being difficult to achieve any effect of caffeine. On the other hand this substance sustained the adult anxious behavior over time in a less stressful paradigm, and this effect was coincident with changes in the SNAP-25, suggesting the involvement of this synaptic protein in the ability of caffeine to preserve changes related to emotionality with aging.


Aging/drug effects , Anxiety/drug therapy , Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Motor Activity/drug effects , Psychotropic Drugs/pharmacology , Aging/physiology , Aging/psychology , Animals , Anxiety/physiopathology , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Dose-Response Relationship, Drug , Drinking Water , Glial Fibrillary Acidic Protein/metabolism , Male , Mice , Motor Activity/physiology , Receptor, Adenosine A2A/metabolism , Synaptosomal-Associated Protein 25/metabolism
3.
Behav Brain Res ; 303: 76-84, 2016 Apr 15.
Article En | MEDLINE | ID: mdl-26774980

Caffeine is the psychostimulant most consumed worldwide. In moderate doses, it affords a beneficial effect in adults and upon aging, but has a deleterious effect during brain development. We now tested if caffeine consumption by rats (0.1, 0.3, 1.0 g/L in the drinking water, only during active cycle and weekdays) during adulthood could revert the potentially negative effects of caffeine during early life. Thus, we compared caffeine intake starting 15 days before mating and lasting either up to weaning (development) or up to adulthood, on behavior and synaptic proteins in male and female rats. Recognition memory was impaired only in female rats receiving caffeine (0.3 and 1.0 g/L) during development, coincident with increased proBDNF and unchanged BDNF levels in the hippocampus. Caffeine in both treatment regimens caused hyperlocomotion only in male rats, whereas anxiety-related behavior was attenuated in both sexes by caffeine (1.0 g/L) throughout life. Both caffeine treatment regimens decreased GFAP (as an astrocyte marker) and SNAP-25 (as a nerve terminals marker) in the hippocampus from male rats. TrkB receptor was decreased in the hippocampus from both sexes and treatment regimens. These findings revealed that caffeine intake during a specific time window of brain development promotes sex-dependent behavioral outcomes related to modification in BDNF signaling. Furthermore, caffeine throughout life can overcome the deleterious effects of caffeine on recognition memory during brain development in female rats.


Brain/drug effects , Caffeine/administration & dosage , Central Nervous System Stimulants/administration & dosage , Memory Disorders/chemically induced , Animals , Anxiety , Brain/growth & development , Brain/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Caffeine/adverse effects , Central Nervous System Stimulants/adverse effects , Female , Glial Fibrillary Acidic Protein/metabolism , Male , Motor Activity/drug effects , Rats , Rats, Wistar , Recognition, Psychology/drug effects , Synaptosomal-Associated Protein 25/metabolism
4.
Int J Dev Neurosci ; 36: 45-52, 2014 Aug.
Article En | MEDLINE | ID: mdl-24862851

Caffeine is the psychostimulant most consumed worldwide. However, little is known about its effects during fetal brain development. In this study, adult female Wistar rats received caffeine in drinking water (0.1, 0.3 and 1.0 g/L) during the active cycle in weekdays, two weeks before mating and throughout pregnancy. Cerebral cortex and hippocampus from embryonic stages 18 or 20 (E18 or E20, respectively) were collected for immunodetection of the following synaptic proteins: brain-derived neurotrophic factor (BDNF), TrkB receptor, Sonic Hedgehog (Shh), Growth Associated Protein 43 (GAP-43) and Synaptosomal-associated Protein 25 (SNAP-25). Besides, the estimation of NeuN-stained nuclei (mature neurons) and non-neuronal nuclei was verified in both brain regions and embryonic periods. Caffeine (1.0 g/L) decreased the body weight of embryos at E20. Cortical BDNF at E18 was decreased by caffeine (1.0 g/L), while it increased at E20, with no major effects on TrkB receptors. In the hippocampus, caffeine decreased TrkB receptor only at E18, with no effects on BDNF. Moderate and high doses of caffeine promoted an increase in Shh in both brain regions at E18, and in the hippocampus at E20. Caffeine (0.3g/L) decreased GAP-43 only in the hippocampus at E18. The NeuN-stained nuclei increased in the cortex at E20 by lower dose and in the hippocampus at E18 by moderate dose. Our data revealed that caffeine transitorily affect synaptic proteins during fetal brain development. The increased number of NeuN-stained nuclei by prenatal caffeine suggests a possible acceleration of the telencephalon maturation. Although some modifications in the synaptic proteins were transient, our data suggest that caffeine even in lower doses may alter the fetal brain development.


Brain/metabolism , Caffeine/toxicity , Central Nervous System Stimulants/toxicity , Fetal Development/drug effects , Nerve Tissue Proteins/metabolism , Prenatal Exposure Delayed Effects , Synapses/metabolism , Age Factors , Animals , Animals, Newborn , Brain/pathology , Brain-Derived Neurotrophic Factor/metabolism , Caffeine/metabolism , Dose-Response Relationship, Drug , Embryo, Mammalian , Female , Hedgehog Proteins/genetics , Hedgehog Proteins/metabolism , Nerve Tissue Proteins/genetics , Neurons/metabolism , Neurons/pathology , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Prenatal Exposure Delayed Effects/pathology , Prenatal Exposure Delayed Effects/physiopathology , Rats , Rats, Wistar , Signal Transduction/drug effects , Synapses/drug effects
5.
Neurochem Int ; 63(6): 594-609, 2013 Nov.
Article En | MEDLINE | ID: mdl-24055856

Caffeine is certainly the psychostimulant substance most consumed worldwide. Over the past years, chronic consumption of caffeine has been associated with prevention of cognitive decline associated to aging and mnemonic deficits of brain disorders. While its preventive effects have been reported extensively, the cognitive enhancer properties of caffeine are relatively under debate. Surprisingly, there are scarce detailed ontogenetic studies focusing on neurochemical parameters related to the effects of caffeine during prenatal and earlier postnatal periods. Furthermore, despite the large number of epidemiological studies, it remains unclear how safe is caffeine consumption during pregnancy and brain development. Thus, the purpose of this article is to review what is currently known about the actions of caffeine intake on neurobehavioral and adenosinergic system during brain development. We also reviewed other neurochemical systems affected by caffeine, but not only during brain development. Besides, some recent epidemiological studies were also outlined with the control of "pregnancy signal" as confounding variable. The idea is to tease out how studies on the impact of caffeine consumption during brain development deserve more attention and further investigation.


Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Animals , Behavior, Animal/drug effects , Brain/drug effects , Brain/growth & development , Caffeine/metabolism , Central Nervous System Stimulants/metabolism , Cognition Disorders/prevention & control , Female , Neurotransmitter Agents/metabolism , Pregnancy
6.
Neuropharmacology ; 64: 153-9, 2013 Jan.
Article En | MEDLINE | ID: mdl-22841916

Beneficial effects of caffeine on memory processes have been observed in animal models relevant to neurodegenerative diseases and aging, although the underlying mechanisms remain unknown. Because brain-derived neurotrophic factor (BDNF) is associated with memory formation and BDNF's actions are modulated by adenosine receptors, the molecular targets for the psychostimulant actions of caffeine, we here compare the effects of chronic caffeine (1 mg/mL drinking solution for 30 days) on short- and long term memory and on levels of hippocampal proBDNF, mature BDNF, TrkB and CREB in young (3 month old) and middle-aged (12 month old) rats. Caffeine treatment substantially reduced i) age-related impairments in the two types of memory in an inhibitory avoidance paradigm, and ii) parallel increases in hippocampal BDNF levels. In addition, chronic caffeine increased proBDNF and CREB concentrations, and decreased TrkB levels, in hippocampus regardless of age. These data provide new evidence in favor of the hypothesis that modifications in BDNF and related proteins in the hippocampus contribute to the pro-cognitive effects of caffeine on age-associated losses in memory encoding. This article is part of a Special Issue entitled 'Cognitive Enhancers'.


Aging , Brain-Derived Neurotrophic Factor/metabolism , Caffeine/therapeutic use , Cognitive Dysfunction/prevention & control , Hippocampus/metabolism , Neurons/metabolism , Nootropic Agents/therapeutic use , Protein Precursors/metabolism , Animals , Avoidance Learning , Behavior, Animal , Central Nervous System Stimulants/therapeutic use , Cognitive Dysfunction/metabolism , Cyclic AMP Response Element-Binding Protein/metabolism , Hippocampus/growth & development , Male , Memory, Long-Term , Memory, Short-Term , Neural Inhibition , Rats , Rats, Wistar , Receptor, trkB/metabolism
7.
Life Sci ; 92(2): 137-42, 2013 Feb 07.
Article En | MEDLINE | ID: mdl-23201428

AIMS: The establishment of a genetic knockout murine model of glutaric acidemia type I (GAI) with complete loss of glutaryl-CoA dehydrogenase (GCDH) activity has been used to investigate the pathological mechanisms underlying neurological symptoms in this disorder. However, very little has been reported on the neurobehavior of GCDH deficient mice (Gcdh(-/-)). MAIN METHODS: In the present study we evaluated physical (body and weight gain) and neuromotor development (appearance of coat, upper incisor eruption, eye-opening day, motor coordination, muscular strength and climbing), as well as cognitive behavior (inhibitory avoidance) in Gcdh(-/-), as compared to wild type (WT) mice. KEY FINDINGS: We found that Gcdh(-/-) mice did not differ in body and weight gain, appearance of coat, upper incisor eruption, motor coordination and muscular strength, but had a significant delayed eye opening, implying a mild impairment of neurodevelopment in these animals. Furthermore, the climbing behavior was significantly higher in Gcdh(-/-) as compared to WT mice, suggesting an altered dopaminergic function. Finally, Gcdh(-/-) mice presented a deficit of short- and long-term memories in the inhibitory avoidance task. SIGNIFICANCE: Although it is difficult to extrapolate the present findings to the human condition, our present data are particularly interesting in view of the psychomotor/mental delay that occurs in a significant number of GAI patients with no previous history of acute encephalopathy with striatum destruction. Strict and early treatment possibly associated with novel therapies seems therefore important to prevent learning/memory disabilities in GAI patients.


Glutaryl-CoA Dehydrogenase/deficiency , Animals , Avoidance Learning/physiology , Behavior, Animal/physiology , Disease Models, Animal , Glutaryl-CoA Dehydrogenase/genetics , Male , Mice , Mice, Knockout/genetics , Mice, Knockout/growth & development , Mice, Knockout/physiology , Muscle Strength/genetics , Muscle Strength/physiology , Pain Threshold/physiology , Postural Balance/genetics , Postural Balance/physiology , Psychomotor Performance/physiology
8.
Prog Neuropsychopharmacol Biol Psychiatry ; 36(1): 198-204, 2012 Jan 10.
Article En | MEDLINE | ID: mdl-22064330

Physical exercise protocols have varied widely across studies raising the question of whether there is an optimal intensity, duration and frequency that would produce maximal benefits in attenuating symptoms related to anxiety disorders. Although physical exercise causes modifications in neurotransmission systems, the involvement of neuromodulators such as adenosine has not been investigated after chronic exercise training. Anxiety-related behavior was assessed in the elevated plus-maze in adult and middle-aged rats submitted to 8 weeks of treadmill running 1, 3 or 7 days/week. The speed of running was weekly adjusted to maintain moderate intensity. The hippocampal adenosine A1 and A2A receptors densities were also assessed. Treadmill running protocol was efficient in increasing physical exercise capacity in adult and middle-aged rats. All frequencies of treadmill running equally decreased the time spent in the open arms in adult animals. Middle-aged treadmill control rats presented lower time spent in the open arms than adult treadmill control rats. However, treadmill running one day/week reversed this age effect. Adenosine A1 receptor was not changed between groups, but treadmill running counteracted the age-related increase in adenosine A2A receptors. Although treadmill running, independent from frequency, triggered anxiety in adult rats and treadmill running one day/week reversed the age-related anxiety, no consistent relationship was found with hippocampal adenosine receptors densities. Thus, our data suggest that as a complementary therapy in the management of mental disturbances, the frequency and intensity of physical exercise should be taken into account according to age. Besides, this is the first study reporting the modulation of adenosine receptors after chronic physical exercise, which could be important to prevent neurological disorders associated to increase in adenosine A2A receptors.


Anxiety/metabolism , Exercise Test , Hippocampus/metabolism , Receptor, Adenosine A1/metabolism , Receptor, Adenosine A2A/metabolism , Running/physiology , Aging/physiology , Aging/psychology , Animals , Anxiety/psychology , Exercise Test/methods , Exercise Test/psychology , Male , Rats , Rats, Wistar , Running/psychology
9.
Prog Neuropsychopharmacol Biol Psychiatry ; 35(1): 169-76, 2011 Jan 15.
Article En | MEDLINE | ID: mdl-21044657

Methylphenidate (MPH) is the preferred treatment used for attention-deficit/hyperactivity disorder (ADHD). Recently, misuse for MPH due to its apparent cognitive enhancer properties has been reported. Adenosine is a neuromodulator known to exert influence on the dopaminergic neurotransmission, which is the main pharmacological target of MPH. We have reported that an overdosage of MPH up-regulates adenosine A(1) receptors in the frontal cortex, but this receptor was not involved in its anxiolytic effects. In this study, the role of adenosine A(1) receptor was investigated on MPH-induced effects on aversive and recognition memory in adult mice. Adult mice received acute and chronic (15 days) administration of methylphenidate (5mg/kg, i.p.), or an acute overdosage (50mg/kg, i.p) in order to model misuse. Memory was assessed in the inhibitory avoidance and object recognition task. Acute administration 5mg/kg improved whereas 50mg/kg disrupted recognition memory and decreased performance in the inhibitory avoidance task. Chronic administration did not cause any effect on memory, but decreased adenosine A(1) receptors immunocontent in the frontal cortex. The selective adenosine A(1) receptor antagonist, (DPCPX 1mg/kg, i.p.), prevented methylphenidate-triggered recognition memory impairment. Our findings showed that recognition memory rather than aversive memory was differently affected by acute administration at both doses. Memory recognition was fully impaired by the overdosage, suggesting that misuse can be harmful for cognitive functions. The adenosinergic system via A(1) receptors may play a role in the methylphenidate actions probably by interfering with dopamine-enhancing properties of this drug.


Central Nervous System Stimulants/toxicity , Memory Disorders , Methylphenidate/toxicity , Receptor, Adenosine A1/metabolism , Recognition, Psychology/drug effects , Adenosine A1 Receptor Antagonists/administration & dosage , Analysis of Variance , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Escape Reaction/drug effects , Exploratory Behavior/drug effects , Gene Expression Regulation/drug effects , Hippocampus/drug effects , Hippocampus/metabolism , Inhibition, Psychological , Male , Memory Disorders/chemically induced , Memory Disorders/metabolism , Memory Disorders/prevention & control , Mice , Recognition, Psychology/physiology , Xanthines/administration & dosage
10.
Brain Res ; 1357: 62-9, 2010 Oct 21.
Article En | MEDLINE | ID: mdl-20699089

In recent years misuse of methylphenidate (MPH) has been reported. The main pharmacological target of methylphenidate is the dopaminergic system. Adenosine is a neuromodulator that influences the dopaminergic neurotransmission, but studies on MPH and adenosine are still lacking. In this study, adult mice were acutely treated with MPH (5mg/kg, i.p.) and to model misuse, they received an acute overdosage (50mg/kg, i.p). The involvement of adenosine A(1) receptors in anxiety-related behavior and locomotor and exploratory activity was examined. The administration of methylphenidate (5 and 50mg/kg) 30 min before the exposure to open field arena did not modify locomotor activity. The anxiolytic-like behavior was observed with both doses of MPH as revealed by the increase on the number of entries and the time spent in the open arms in the elevated plus-maze. Pre treatment with selective adenosine A(1) receptor antagonist (DPCPX 1mg/kg, i.p.) did not prevent anxiolytic effect caused by MPH 50mg/kg. Immunoblotting of frontal cortex and hippocampal extracts revealed that MPH 50mg/kg increased 88% adenosine A(1) receptor density in the frontal cortex. Extracts from hippocampus did not reveal any differences in the adenosine A(1) receptor density. Our findings ruled out the participation of adenosine A(1) receptors on the MPH-triggered anxiolytic effects. However, the density of adenosine A(1) receptors increased in a brain area strictly involved in the MPH-mediated effects. Thus, the adenosinergic system may play a role in the methylphenidate actions in the central nervous system.


Anxiety/drug therapy , Frontal Lobe/metabolism , Hippocampus/metabolism , Methylphenidate/pharmacology , Motor Activity/drug effects , Receptor, Adenosine A1/metabolism , Adenosine A1 Receptor Antagonists/pharmacology , Analysis of Variance , Animals , Anxiety/metabolism , Blotting, Western , Central Nervous System Stimulants/pharmacology , Male , Mice , Motor Activity/physiology , Xanthines/pharmacology
11.
Behav Brain Res ; 214(2): 254-9, 2010 Dec 25.
Article En | MEDLINE | ID: mdl-20553765

Caffeine is a psychostimulant with positive effects on cognition. Recent studies have suggested the participation of the cholinergic system in the effects of caffeine on wakefulness. However, there are few studies assessing the contribution of cholinergic system in the cognitive enhancer properties of caffeine. In the present study, the effects of a dose and schedule of administration of caffeine that improved memory recognition were investigated on scopolamine-induced impairment of memory in adult mice. Inhibitory avoidance and novel object recognition tasks were used to assess learning and memory. Caffeine (10mg/kg, i.p.) was administered during 4 consecutive days, and the treatment was interrupted 24h before scopolamine administration (2mg/kg, i.p.). Scopolamine was administered prior to or immediately after training. Short-term and long-term memory was evaluated in both tasks. In the novel object recognition task, pre treatment with caffeine prevented the disruption of short- and long-term memory by scopolamine. In the inhibitory avoidance task, caffeine prevented short- but not long-term memory disruption by pre training administration of scopolamine. Caffeine prevented short- and long-term memory disruption by post training administration of scopolamine. Both treatments did not affect locomotor activity of the animals. These findings suggest that acute treatment with caffeine followed by its withdrawal may be effective against cholinergic-induced disruption of memory assessed in an aversive and non-aversive task. Finally, our results revealed that the cholinergic system is involved in the positive effects of caffeine on cognitive functions.


Avoidance Learning/drug effects , Caffeine/pharmacology , Memory/drug effects , Recognition, Psychology/drug effects , Scopolamine/antagonists & inhibitors , Animals , Caffeine/administration & dosage , Drug Administration Schedule , Drug Interactions , Male , Mice , Mice, Inbred Strains , Motor Activity/drug effects , Scopolamine/pharmacology
12.
Physiol Behav ; 99(1): 17-21, 2010 Jan 12.
Article En | MEDLINE | ID: mdl-19825381

Environmental enrichment (EE) is an experimental model for studying neuroplasticity. EE is used to investigate behavioral modifications associated with gene-environmental interaction. The object recognition task (ORT) evaluates animals' ability to learn about their environment, which depends on their innate instinct. By using young CF1 mice, the present study evaluated the effect of 8 weeks of EE on the ORT. Our results indicate that EE decreased the time the animals spent exploring familiar and unfamiliar objects and total time spent exploring both objects, without affecting the capacity of discrimination of objects. These findings indicate a more propitious behavior for species survival in animals subjected to EE, including rapid exploration and learning about the environment.


Environment , Recognition, Psychology/physiology , Analysis of Variance , Animals , Behavior, Animal , Brain-Derived Neurotrophic Factor/metabolism , Discrimination, Psychological/physiology , Exploratory Behavior/physiology , Gene Expression Regulation/physiology , Hippocampus/metabolism , Male , Mice , Receptor, trkB/metabolism
...